Kawasaki Disease: Diagnosis, Coronary Monitoring, and Risk Stratification

Summary

• Complete Kawasaki disease (KD) requires fever plus ≥4 of 5 principal clinical features; diagnosis can be made at 4 days of fever with ≥4 features present, or at 3 days in classic presentations by experienced clinicians [1,2].
• Incomplete KD (25-30% of cases) requires CRP ≥3.0 mg/dL or ESR ≥40 mm/hr plus ≥3 supplemental laboratory criteria, or a coronary z-score ≥2.5 [1,2].
• IVIG (2 g/kg single infusion) given within 10 days of illness reduces coronary artery aneurysm (CAA) incidence from 20-25% untreated to less than 4% [1,2].
• 10-15% of patients are IVIG-resistant (persistent/recrudescent fever ≥36 hours post-infusion); the Kobayashi score performs poorly outside Japanese populations (summary C-statistic 0.65) [1,3].
• A coronary z-score ≥2.5 defines a true aneurysm; small and medium CAAs (z <10) show near-universal regression, while large/giant CAAs (z ≥10) carry 29-48% risk of coronary events on long-term follow-up [1,2].
• MIS-C overlaps with KD but differs in age distribution, laboratory profile, and rate of shock; only 25-50% of MIS-C patients meet full KD criteria [1].

Diagnostic criteria

Complete Kawasaki disease

Fever plus ≥4 of the 5 principal clinical features:

1. Bilateral bulbar conjunctival injection without exudate
2. Oral mucosal changes (erythema, cracked lips, strawberry tongue, diffuse oropharyngeal erythema)
3. Polymorphous rash (maculopapular, diffuse erythroderma, or erythema multiforme-like)
4. Extremity changes (acute: erythema/edema of hands and feet; subacute: periungual desquamation)
5. Cervical lymphadenopathy (≥1.5 cm diameter, usually unilateral)

Open the Kawasaki Diagnostic Criteria tool →

Incomplete Kawasaki disease

Approximately 25-30% of children with KD do not meet complete criteria [1,2]. Consider incomplete KD in any infant or child with unexplained fever ≥5 days and 2-3 principal features. Infants under 6 months carry the highest risk for incomplete presentation and coronary complications.

Laboratory supplemental criteria (require ≥3 when CRP ≥3.0 mg/dL or ESR ≥40 mm/hr):

• Albumin ≤3.0 g/dL
• Anemia for age
• Elevated ALT
• Platelets ≥450,000/μL after day 7
• WBC ≥15,000/μL
• Urine ≥10 WBC/high-power field

Echocardiographic criterion: coronary z-score ≥2.5 (left anterior descending or right coronary artery) has very high specificity and supports treatment even with incomplete clinical features [1,2].

These laboratory and echocardiographic findings are supportive, not standalone diagnostic thresholds. Coronary abnormalities in a febrile child with compatible features essentially confirm the diagnosis.

Open the Coronary Z-Score Calculator →

Clinical pearl. A 4-month-old with 6 days of fever, conjunctival injection, and cracked lips (2 principal features) has CRP 8.2 mg/dL, albumin 2.8 g/dL, hemoglobin 9.1 g/dL, and platelets 520,000/μL. This meets laboratory criteria for incomplete KD (CRP ≥3.0 mg/dL plus 3 supplemental findings: hypoalbuminemia, anemia, thrombocytosis). IVIG is indicated given the high-risk age group and supportive labs, regardless of echocardiogram result.

Clinical pearl. A 2-year-old with 7 days of fever, rash, and 2.0 cm cervical node (2 principal features) has LAD z-score 3.2 on echocardiogram. A z-score ≥2.5 in a febrile child with compatible features essentially confirms KD; IVIG should start immediately, and coronary involvement at presentation qualifies the patient as high-risk.

Caution. A normal echocardiogram in the first week does not exclude KD. A 3-year-old with 3 principal features, elevated CRP but only 1 supplemental criterion, and normal coronary z-scores (<2.0) remains a borderline case warranting treatment given clinical suspicion. Coronary dilation can develop later, so serial echocardiography at 2 weeks and 6-8 weeks is required regardless of the initial study.

Caution. Low inflammatory markers with respiratory symptoms point away from KD. If CRP <3.0 mg/dL and ESR <40 mm/hr, KD is unlikely, but persistent fever beyond day 5 without alternative explanation still warrants reassessment with repeat labs and echocardiography.

Differential diagnosis

Consider before treatment: scarlet fever (sandpaper rash, positive streptococcal testing), measles (cough, coryza, Koplik spots), drug hypersensitivity reactions, viral infections (adenovirus, enterovirus), and MIS-C.

Findings atypical for KD: oral ulcerations, exudative pharyngitis, exudative or unilateral conjunctivitis, vesicular rash.

Kawasaki disease vs. MIS-C

MIS-C shares fever, mucocutaneous findings, and potential coronary involvement with KD, but only 25-50% of MIS-C patients meet full KD criteria [1].

Younger children with MIS-C are more likely to present with KD-like features, while older children more often develop myocarditis and shock. This age-dependent phenotype partly explains the clinical overlap.

Risk stratification for IVIG resistance

Approximately 10-15% of patients do not respond to initial IVIG, defined as persistent or recrudescent fever ≥36 hours after infusion completion. These patients carry increased risk for coronary complications.

Kobayashi score (developed in Japanese populations): sodium ≤133 mmol/L, illness day ≤4 at treatment, AST ≥100 IU/L, neutrophils ≥80%, CRP ≥10 mg/dL, age ≤12 months, platelets ≤300,000/μL.

Caution. The Kobayashi score performs poorly in non-Japanese populations. A 2023 meta-analysis found a summary C-statistic of only 0.65 in external validation studies [3]. Current AHA guidance states Japanese risk scores "have not performed well in North American cohorts" [1].

Open the Kobayashi Score Calculator →

High-risk features warranting consideration of intensified initial therapy: coronary z-score ≥2.5 at diagnosis, age <6 months, high-risk category by validated score. Integrate multiple factors and involve a clinician experienced in KD management before intensifying therapy.

Initial treatment

IVIG: 2 g/kg single infusion over 8-12 hours, within the first 10 days of illness, ideally by day 5-7 of fever. Can still be given after day 10 if fever, elevated inflammatory markers, or coronary abnormalities persist [1,2].

Aspirin dosing (acute phase):

Multiple retrospective studies and meta-analyses found no significant differences in CAA rates, IVIG resistance, or length of stay across aspirin doses. The 2024 AHA update notes increasing evidence that medium- or high-dose aspirin in the acute phase is likely not associated with improved coronary outcomes [1].

After defervescence

References

1. Jone PN, Tremoulet A, Choueiter N, et al. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. Circulation. 2024;150(23):e481-e500.
2. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e999.
3. Kuniyoshi Y, Tsujimoto Y, Banno M, et al. Prediction Models for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Meta-Analysis. Pediatrics. 2023;151(5):e2022059175.